Warning: file_get_contents(http://tehnika-news.ru/shells.txt): failed to open stream: Connection refused in /var/sites/p/paperbomb.com/public_html/meds2/1/index.php on line 2
besponsa launch

besponsa launch

Перейти к контенту

Главное меню:

Разное
besponsa launch
Welcome to BESPONSA® | BESPONSA®, Pfizer Receives U.S. FDA Approval for BESPONSA , Pfizer's orphan drug Besponsa for relapsed ALL gets first , Pfizer wins approval for blood cancer drug Besponsa , BESPONSA® Approved in the EU for Adult Patients with , Besponsa for Acute Lymphoblastic Leukemia Approved by FDA, , , .
BESPONSA can cause liver problems that can be severe, life-threatening, or fatal, including a condition called veno-occlusive disease (VOD). This condition can occur during treatment with BESPONSA or following subsequent treatment with a stem cell transplant. This condition was more common in patients who had elevated liver tests or who received dual alkylating agents in preparation for their stem cell transplant. Patients may be at a higher risk of VOD if they: . 81% (88/109) of patients achieved remission * with BESPONSA compared to 29% (32/109) of patients with chemotherapy * Remission means that no leukemia cells can be seen when looking at bone marrow under a microscope.. BESPONSA is the first and only CD22-directed antibody-drug conjugate indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BESPONSA® (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).1 BESPONSA was reviewed and approved under the FDA’s Breakthrough .
Pfizer's orphan drug Besponsa for relapsed ALL gets first launch worldwide in Germany. “The approval of Besponsa is an important step forward for adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia, a rare disease that can be fatal within a matter of . NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE:PFE) today announced that the European Commission has approved BESPONSA ® (inotuzumab ozogamicin) as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL).. Besponsa is a CD22-antibody therapy that functions by binding to the ALL cancer cells that display the CD22 antigen on their surface. Through this binding, the drug initiates a response which resulting in the attenuation of growth of these cancer cells.. . .
 
Copyright 2019. All rights reserved.
Назад к содержимому | Назад к главному меню